Ratings CYBERDYNE Inc.

Equities

7779

JP3311530004

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-07-05 am EDT			5-day change	1st Jan Change
206 ^JPY	+0.49%		-2.83%	-8.04%

May. 15	U.S. FDA Becomes the world's First to Clear Smaller Model of Medical HAL and Expanded Indication for Cerebral Palsy	CI
Apr. 30	Cyberdyne May Book 18 Million Yen Provision for Doubtful Accounts in Fiscal 2024 Due to Non-collectable Claims	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Thanks to a sound financial situation, the firm has significant leeway for investment.
The company's share price in relation to its net book value makes it look relatively cheap.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company sustains low margins.
With an enterprise value anticipated at 4.77 times the sales for the current fiscal year, the company turns out to be overvalued.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Over the past four months, analysts' average price target has been revised downwards significantly.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
CYBERDYNE INC.	-8.04%	269M		D+
HCA HEALTHCARE, INC.	+20.64%	85.53B		C+
CVS HEALTH CORPORATION	-28.19%	71.18B		B-
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+0.99%	26.76B		C+
FRESENIUS SE & CO. KGAA	+4.35%	17.43B		A-
LABCORP HOLDINGS INC.	-10.31%	17.18B		B
QUEST DIAGNOSTICS INCORPORATED	+2.19%	15.65B		A-
NATERA, INC.	+78.22%	13.71B		C-
PURE HEALTH HOLDING	-25.09%	13.1B	-	-
TENET HEALTHCARE CORPORATION	+79.75%	13.27B		C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes